JP2022540611A5 - - Google Patents
Info
- Publication number
- JP2022540611A5 JP2022540611A5 JP2022501134A JP2022501134A JP2022540611A5 JP 2022540611 A5 JP2022540611 A5 JP 2022540611A5 JP 2022501134 A JP2022501134 A JP 2022501134A JP 2022501134 A JP2022501134 A JP 2022501134A JP 2022540611 A5 JP2022540611 A5 JP 2022540611A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antibody
- antigen
- binding fragment
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025061352A JP2025156278A (ja) | 2019-07-11 | 2025-04-02 | Dll3をターゲッティングする抗体とその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962872915P | 2019-07-11 | 2019-07-11 | |
| US62/872,915 | 2019-07-11 | ||
| PCT/US2020/041282 WO2021007371A1 (en) | 2019-07-11 | 2020-07-08 | Dll3-targeting antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061352A Division JP2025156278A (ja) | 2019-07-11 | 2025-04-02 | Dll3をターゲッティングする抗体とその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022540611A JP2022540611A (ja) | 2022-09-16 |
| JP2022540611A5 true JP2022540611A5 (cg-RX-API-DMAC7.html) | 2023-07-12 |
| JP7661299B2 JP7661299B2 (ja) | 2025-04-14 |
Family
ID=74115317
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022501134A Active JP7661299B2 (ja) | 2019-07-11 | 2020-07-08 | Dll3をターゲッティングする抗体とその使用 |
| JP2025061352A Pending JP2025156278A (ja) | 2019-07-11 | 2025-04-02 | Dll3をターゲッティングする抗体とその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061352A Pending JP2025156278A (ja) | 2019-07-11 | 2025-04-02 | Dll3をターゲッティングする抗体とその使用 |
Country Status (13)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2718257T3 (cg-RX-API-DMAC7.html) * | 2014-05-30 | 2018-04-14 | ||
| US12441789B2 (en) * | 2019-07-11 | 2025-10-14 | Memorial Sloan Kettering Cancer Center | DLL3-targeting antibodies and uses thereof |
| EP4277665A1 (en) * | 2021-01-13 | 2023-11-22 | Memorial Sloan Kettering Cancer Center | Anti-dll3 antibody-drug conjugate |
| CN117425501A (zh) * | 2021-01-13 | 2024-01-19 | 纪念斯隆凯特琳癌症中心 | 抗体-吡咯并苯二氮䓬衍生物缀合物 |
| US20240239878A1 (en) * | 2021-05-08 | 2024-07-18 | Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. | Binding molecule against dll3 and use thereof |
| CA3230627A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Antigen recognizing receptors targeting dll3 and uses thereof |
| WO2023034557A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Radioligand binding to anti-dll3 antibodies for pretargeted pet imaging and therapeutic uses thereof |
| JP2024534892A (ja) * | 2021-09-02 | 2024-09-26 | メモリアル スローン ケタリング キャンサー センター | 抗dll3抗体及びその使用 |
| TW202346346A (zh) * | 2021-12-23 | 2023-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗dll3抗體、其抗體-藥物偶聯物及其醫藥用途 |
| IL314678A (en) | 2022-02-27 | 2024-10-01 | Boehringer Ingelheim Int | Bispecific antibodies against cd277 and a tumor-antigen |
| CN116003628B (zh) * | 2022-08-15 | 2026-08-04 | 南京博安生物技术有限公司 | 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用 |
| WO2025184421A1 (en) * | 2024-02-28 | 2025-09-04 | Juno Therapeutics, Inc. | Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1838968A (zh) | 2003-08-08 | 2006-09-27 | 艾伯吉尼斯公司 | 针对甲状旁腺激素(pth)之抗体和其用途 |
| EP2094307A4 (en) * | 2006-11-08 | 2015-08-26 | Macrogenics West Inc | TES7 AND THEREO BINDING ANTIBODIES |
| PL2530091T3 (pl) | 2010-01-29 | 2018-08-31 | Chugai Seiyaku Kabushiki Kaisha | Przeciwciało przeciwko dll3 |
| EP2598532B1 (en) | 2010-07-30 | 2017-07-12 | Gianluca Moroncini | Epitopes of the human pdgf receptor able to bind human auto-antibodies, antibodies and uses thereof |
| ES2886123T3 (es) * | 2012-01-31 | 2021-12-16 | Regeneron Pharma | Anticuerpos anti-asic1 y usos de los mismos |
| CN104520324A (zh) * | 2012-02-24 | 2015-04-15 | 施特姆森特Rx股份有限公司 | Dll3调节剂及其使用方法 |
| EP3107576A4 (en) * | 2014-02-21 | 2017-09-06 | Abbvie Stemcentrx LLC | Anti-dll3 antibodies and drug conjugates for use in melanoma |
| AR101669A1 (es) | 2014-07-31 | 2017-01-04 | Amgen Res Munich Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
| RS61010B1 (sr) * | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3 |
| US12441789B2 (en) * | 2019-07-11 | 2025-10-14 | Memorial Sloan Kettering Cancer Center | DLL3-targeting antibodies and uses thereof |
-
2020
- 2020-07-08 US US17/622,404 patent/US12441789B2/en active Active
- 2020-07-08 JP JP2022501134A patent/JP7661299B2/ja active Active
- 2020-07-08 AU AU2020310894A patent/AU2020310894A1/en active Pending
- 2020-07-08 PH PH1/2022/550056A patent/PH12022550056A1/en unknown
- 2020-07-08 CN CN202411174923.9A patent/CN119080930A/zh active Pending
- 2020-07-08 BR BR112022000216A patent/BR112022000216A2/pt unknown
- 2020-07-08 WO PCT/US2020/041282 patent/WO2021007371A1/en not_active Ceased
- 2020-07-08 MX MX2022000325A patent/MX2022000325A/es unknown
- 2020-07-08 CN CN202080062231.9A patent/CN114341182B/zh active Active
- 2020-07-08 CN CN202411174926.2A patent/CN118955717A/zh active Pending
- 2020-07-08 EP EP20836805.0A patent/EP3997127A4/en active Pending
- 2020-07-08 KR KR1020227004114A patent/KR20220034167A/ko active Pending
- 2020-07-08 CA CA3146566A patent/CA3146566A1/en active Pending
-
2022
- 2022-01-03 IL IL289585A patent/IL289585A/en unknown
- 2022-02-04 CO CONC2022/0001195A patent/CO2022001195A2/es unknown
-
2025
- 2025-04-02 JP JP2025061352A patent/JP2025156278A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7235256B2 (ja) | 重症熱性血小板減少症候群ウイルスの外膜糖タンパク質に結合する抗体及びその用途 | |
| CN105579471B (zh) | 结合人程序性死亡配体1(pd-l1)的抗体 | |
| JP7624497B2 (ja) | ヒトpd-l2抗体およびその使用方法 | |
| JP2009100745A5 (cg-RX-API-DMAC7.html) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| US12325747B2 (en) | Human PD-L1 antibodies and methods of use therefor | |
| JP2005518789A5 (cg-RX-API-DMAC7.html) | ||
| JP7713995B2 (ja) | ヒトpd-l1およびpd-l2に対する二重特異性抗体およびその使用方法 | |
| JP2024506315A5 (cg-RX-API-DMAC7.html) | ||
| JP2022538117A5 (cg-RX-API-DMAC7.html) | ||
| JP2023537002A5 (cg-RX-API-DMAC7.html) | ||
| US20250129167A1 (en) | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor | |
| JP2024540148A5 (cg-RX-API-DMAC7.html) | ||
| CN112979795A (zh) | 抗体组合产品及其在新冠肺炎检测中应用 | |
| RU2021139258A (ru) | Dll3-нацеливающие антитела и их применения | |
| CN118240079A (zh) | 抗脂联素抗体、检测脂联素的试剂和试剂盒 | |
| CN120424221B (zh) | 靶向德曲妥珠单抗的抗体及其用途 | |
| TW201915016A (zh) | 單株抗體或其抗原結合片段及其用途 | |
| JP2025512888A (ja) | ヒトpd-l1およびpd-l2に対する二重特異性抗体ならびにその使用方法 | |
| CN121975014A (zh) | 抗dll3的抗体及其相关产品和应用 | |
| KR20250064725A (ko) | 사스 코로나바이러스 2 중화를 위한 이뮤노글로불린 a 항체 및 이의 용도 | |
| JP2024531913A5 (cg-RX-API-DMAC7.html) |